Stock Watch: Novo Edges Ahead Of Lilly In GLP-1 Agonist Battle

Gold Only Glitters If You Can Manufacture It

 
• By Andy Smith

The sales performances of the GLP-1 agonists dominated the earnings of Novo Nordisk and Lilly, with both stocks hitting 52-week highs after their results. But one moved ahead of the other in an important strategic bottleneck.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

More from Stock Watch

More from Business